The Utility of the BRCAvantage Test

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its prior HER2-low indication.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan in breast cancer.

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast cancer and the need for HER2-negative data with T-DXd.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

For Heart Health Month, Amy Ahnert, MD, Director, Women’s Heart Program at Morristown Medical Center, Atlantic Health System, discussed the link between cardiovascular disease and breast cancer.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.